Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells (Q39167525)

9 September 2017

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells (English)

1 reference

protein-protein interaction

9 September 2017

1 reference

9

1 reference

9 September 2017

Lars Petter Jordheim

1

1 reference

9 September 2017

Khaled H Barakat

2

1 reference

9 September 2017

Laurence Heinrich-Balard

3

1 reference

9 September 2017

Eva-Laure Matera

4

1 reference

9 September 2017

Emeline Cros-Perrial

5

1 reference

9 September 2017

Karima Bouledrak

6

1 reference

9 September 2017

Rana El Sabeh

7

1 reference

9 September 2017

Rolando Perez-Pineiro

8

1 reference

9 September 2017

Richard Cohen

10

1 reference

9 September 2017

Jack Tuszynski

11

1 reference

9 September 2017

Charles Dumontet

12

1 reference

9 September 2017

11 April 2013

1 reference

9 September 2017

Molecular Pharmacology

1 reference

9 September 2017

84

1 reference

9 September 2017

12-24

1 reference

9 September 2017

1

1 reference

Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction

9 September 2017

2 references

5 May 2024

https://opencitations.net/index/api/v1/citations/10.1371/JOURNAL.PONE.0051329

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Targeting the MDM2-p53 interaction for cancer therapy

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Principles of Fluorescence Spectroscopy

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Mammalian nucleotide excision repair proteins and interstrand crosslink repair

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

The Amber biomolecular simulation programs

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Computational drug design accommodating receptor flexibility: the relaxed complex scheme

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Scalable molecular dynamics with NAMD

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Kinetics of H2AX phosphorylation after exposure to cisplatin

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Relaxed complex scheme suggests novel inhibitors for the lyase activity of DNA polymerase beta.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

DNA repair in mammalian cells : Nucleotide excision repair: variations on versatility

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Molecular mechanisms of cisplatin resistance

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Validation and use of the MM-PBSA approach for drug discovery

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

An improved relaxed complex scheme for receptor flexibility in computer-aided drug design

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1124/MOL.112.082347

Identifiers

DOI

10.1124/MOL.112.082347

1 reference

9 September 2017

1 reference